In this model, Tregs were first expanded via STAR2 administration in recipient mice before allo-HCT, which led to a significantly prolonged survival and reduced GvHD severity in a TNFR2- and Treg-dependent manner. This evidence concerns the gene TNFRSF1B and graft versus host disease.